Primary study · included by 1 review

LUX‑Lung 3, 2023 (Sequist et al.)

Included by

Oral mucositis risk with EGFR tyrosine kinase inhibitor monotherapies and combination regimens in non-small cell lung cancer: a systematic review and network meta-analysis.

Non-Cochrane · intervention · 2026 · cited as LUX‑Lung 3, 2023 (Sequist et al.) · Supplementary Table S2 (Table1.docx)

The review does not say which of its outcomes this study informs.

1 including review in total.